AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.010

0.000

Volume:4.96M

Turnover:50.25K

Market Cap:43.38M

PE:-0.53

High:0.011

Open:0.010

Low:0.010

Close:0.010

52wk High:0.040

52wk Low:0.009

Shares:4.34B

Float Shares:3.34B

Volume Ratio:0.20

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.019

EPS(LYR):-0.018

ROE:-92.10%

ROA:-28.33%

PB:0.84

PE(LYR):-0.54

Loading ...

Overview Company News Filings

Radiopharm Theranostics - Receives Firm Commitments for A$12.5 Mln Capital Raising

THOMSON REUTERS

Radiopharm Theranostics - no Dose-limiting Toxicities Observed with Rad204 in Phase 1 Trial

THOMSON REUTERS

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of Rad204 in Patients with Advanced Solid Tumors Post-immunotherapy

THOMSON REUTERS

Radiopharm Theranostics Partners with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial

Radiopharm Theranostics Announces Positive Phase 2B Trial Results of Rad 101 for Diagnosis of Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics - Rad101 Shows Preliminary 86% Sensitivity in Six-month Follow-up; Specificity Data Expected Q4 2026

THOMSON REUTERS

Radiopharm Theranostics' Phase 2b Trial of Brain Metastases Diagnosis Agent Meets Primary Endpoint

MT Newswires Live

Radiopharm Theranostics - Requests Trading Halt Pending Announcement on Material Capital Raising

THOMSON REUTERS

Radiopharm Theranostics Receives AU$5.9 Million R&D Tax Refund for Fiscal Year 2025

MT Newswires Live

Starpharma Says Radiopharm Theranostics Collaboration Milestone Triggers AU$500,000 Option Fee

MT Newswires Live

Radiopharm Theranostics Ltd : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $16

THOMSON REUTERS

Despite Recent Gains, Radiopharm Theranostics Insiders Are Still Down AU$29k

Simply Wall St.

Radiopharm Theranostics files Form 3 for Chief Medical Officer Dimitris Voliotis

Radiopharm Theranostics director Paul Hopper files initial beneficial ownership statement

Regis Healthcare to Benefit from Higher Govt Spending on Aged Care, Says Jefferies

MT Newswires Live

Radiopharm Theranostics files Form 3 for CFO Aaron James Laurita

Radiopharm Theranostics Ltd-Financial Services and Company Secretary Changes

THOMSON REUTERS

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

MT Newswires Live

Radiopharm starts first-in-human Phase 1 trial of RAD 402 in advanced prostate cancer

Radiopharm Theranostics Reports Decline in Cash at End of March

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/RAD.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.01,"timestamp":1787292720000,"preClose":0.01,"halted":0,"volume":4959375,"delay":0,"changeRate":0,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.019034,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:12:00 AEST","open":0.01,"high":0.011,"low":0.01,"amount":50250,"amplitude":0.1,"askPrice":0.011,"askSize":1836974,"bidPrice":0.01,"bidSize":14762,"shortable":3,"etf":0,"ttmEps":-0.019034,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.01,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.19748640911225376,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.01,"auctionPrice":0.01,"auctionVolume":178500,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292595380}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-28.33%","roe":"-92.10%","lyrEps":-0.018424,"volumeRatio":0.19748640911225376,"shares":4337549000,"dividePrice":0,"high":0.011,"amplitude":0.1,"preClose":0.01,"low":0.01,"week52Low":0.009,"pbRate":"0.84","psRate":"2.66","week52High":0.04,"institutionHeld":0,"latestPrice":0.01,"committee":-0.984056,"eps":-0.019034,"divideRate":0,"volume":4959375,"delay":0,"ttmEps":-0.019034,"open":0.01,"prevYearClose":0.025,"prevWeekClose":0.011,"prevMonthClose":0.014,"prevQuarterClose":0.019,"fiveDayClose":0.011,"twentyDayClose":0.019,"sixtyDayClose":0.021,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653704554","title":"Radiopharm Theranostics - Receives Firm Commitments for A$12.5 Mln Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2653704554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653704554?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:21","pubTimestamp":1784877673,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nFWN43P1FO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754780","title":"Radiopharm Theranostics - no Dose-limiting Toxicities Observed with Rad204 in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754780?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:05","pubTimestamp":1784718300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA3MMWNN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754735","title":"Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of Rad204 in Patients with Advanced Solid Tumors Post-immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754735?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:05","pubTimestamp":1784718300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA3MMWNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754924","title":"Radiopharm Theranostics Partners with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754924","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754924?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718053,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trialRadiopharm Theranostics partnered with Siemens Healthineers to manufacture and di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL3qgNlv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","BCDF","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","SG9999014013.SGD","BK7067","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","RAD.AU","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754608","title":"Radiopharm Theranostics Announces Positive Phase 2B Trial Results of Rad 101 for Diagnosis of Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754608","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754608?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA39F6Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653544827","title":"Radiopharm Theranostics - Rad101 Shows Preliminary 86% Sensitivity in Six-month Follow-up; Specificity Data Expected Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653544827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653544827?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA39F6Y1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653364567","title":"Radiopharm Theranostics' Phase 2b Trial of Brain Metastases Diagnosis Agent Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2653364567","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653364567?lang=en_us&edition=fundamental","pubTime":"2026-07-22 13:09","pubTimestamp":1784696971,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  said a phase 2b trial of RAD101 in participants with suspected recurrence of brain metastases after radiotherapy met its primary endpoint, according to a Wednesday filing with the Australian bourse.The analysis of the imaging data for all assessed lesions showed 93% concordance between magnetic resonance imaging and PET scans of brain metastases, per the filing.Meanwhile, 14 patients with evaluable six-month data showed preliminary sensitivity of 86%, a gauge of an imaging test's ability to correctly identify patients with disease.The results also showed \"substantial and selective tumor uptake of RAD101,\" supporting its progression into an intended registrational phase 3 program, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653789722","title":"Radiopharm Theranostics - Requests Trading Halt Pending Announcement on Material Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2653789722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653789722?lang=en_us&edition=fundamental","pubTime":"2026-07-22 07:05","pubTimestamp":1784675104,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N173:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648601656","title":"Radiopharm Theranostics Receives AU$5.9 Million R&D Tax Refund for Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2648601656","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648601656?lang=en_us&edition=fundamental","pubTime":"2026-07-03 14:39","pubTimestamp":1783060785,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) received its research and development (R&D) tax refund for the fiscal year 2025, totalling AU$5.9 million, including AU$104,475 in interest, according to a Friday Aus","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634744","title":"Starpharma Says Radiopharm Theranostics Collaboration Milestone Triggers AU$500,000 Option Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634744","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648634744?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:10","pubTimestamp":1783041039,"startTime":"0","endTime":"0","summary":"Starpharma Holdings (ASX:SPL) achieved a milestone under its collaboration with Radiopharm Theranostics (ASX:RAD), triggering an AU$500,000 option fee payable to Starpharma, according to a Friday fili","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPL.AU","BK7067","BK7501","RAD.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815964","title":"Radiopharm Theranostics Ltd : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640815964?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:11","pubTimestamp":1780567878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RADX","RAD.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636098872","title":"Despite Recent Gains, Radiopharm Theranostics Insiders Are Still Down AU$29k","url":"https://stock-news.laohu8.com/highlight/detail?id=2636098872","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636098872?lang=en_us&edition=fundamental","pubTime":"2026-05-17 08:24","pubTimestamp":1778977483,"startTime":"0","endTime":"0","summary":"Some of the losses seen by insiders who purchased AU$138.4k worth of Radiopharm Theranostics Limited ( ASX:RAD ) shares...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/despite-recent-gains-radiopharm-theranostics-insiders-are-st-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/despite-recent-gains-radiopharm-theranostics-insiders-are-st-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633641361","title":"Radiopharm Theranostics files Form 3 for Chief Medical Officer Dimitris Voliotis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633641361","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633641361?lang=en_us&edition=fundamental","pubTime":"2026-05-07 09:09","pubTimestamp":1778116170,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Form 3 showed Chief Medical Officer Dimitris Voliotis holding options to buy 22,972,000 ordinary shares at AUD 0.025, expiring July 1, 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL65lPJy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633674186","title":"Radiopharm Theranostics director Paul Hopper files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633674186","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633674186?lang=en_us&edition=fundamental","pubTime":"2026-05-06 18:09","pubTimestamp":1778062182,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Paul Hopper reported 53.9 million ordinary shares held directly, with additional indirect holdings of 93.57 million shares via Kilinwata Investments Pty Ltd and 250,000 shares held by his spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL4NKFwh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633708962","title":"Regis Healthcare to Benefit from Higher Govt Spending on Aged Care, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2633708962","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633708962?lang=en_us&edition=fundamental","pubTime":"2026-05-05 07:14","pubTimestamp":1777936479,"startTime":"0","endTime":"0","summary":"Regis Healthcare  is expected to reap benefits from higher government funding into aged care sector, Jefferies said Monday in a note, adding that it is awaiting clarity from the upcoming federal budget announcement this month.The government has announced plans for a AU$3 billion investment in aged care, which includes an increased accommodation supplement.The investment firm assumes that if 40% of Regis' residents received a AU$15 higher daily accommodation supplement, the company could see around a 10% boost in EBITDA per place over 12 months. Regis expects fiscal 2026 underlying EBITDA of around AU$135 million.Jefferies is also confident in the company's fiscal 2027 outlook despite near-full occupancy as Regis continues to expand its portfolio and increase the proportion of residents paying Refundable Accommodation Deposit . The company reported average occupancy of 95.9% in mature homes in the third quarter.Jefferies maintained a buy rating and increased its price target by 35% to A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LABU","LU0128526141.USD","RAD","REG.AU","BK4581","RAD.AU","RGS","BK4585","BK4128","XLV","XBI","BK4137","BK4588","BK7113","HCSG","LU0029874061.USD","BK4192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669690","title":"Radiopharm Theranostics files Form 3 for CFO Aaron James Laurita","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669690","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669690?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:52","pubTimestamp":1777600337,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics CFO Aaron James Laurita reported 26,357 ordinary shares in an initial Form 3 filing dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDLc8XzQv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632369800","title":"Radiopharm Theranostics Ltd-Financial Services and Company Secretary Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2632369800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632369800?lang=en_us&edition=fundamental","pubTime":"2026-05-01 07:53","pubTimestamp":1777593207,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUEBFV78N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631757805","title":"Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631757805","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631757805?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:11","pubTimestamp":1777507899,"startTime":"0","endTime":"0","summary":"Regis Healthcare  said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization  of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit  cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","XBI","LABU","LU0029874061.USD","BK4137","RAD.AU","HCSG","BK4581","LU0128526141.USD","RGS","BK4128","BK7113","RAD","BK7067","XLV","BK4192","REG.AU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629298833","title":"Radiopharm starts first-in-human Phase 1 trial of RAD 402 in advanced prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629298833","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629298833?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:12","pubTimestamp":1776942752,"startTime":"0","endTime":"0","summary":"Radiopharm completed enrollment in Phase 2b imaging trial of 18F-RAD101 in recurrent brain metastases, building on interim results already presented that supported performance versus MRI.Management flagged that confirmation of these findings would trigger preparation for a multi-center, multi-country Phase 3 registrational study.Initial Phase 0/1 data for 177Lu-RAD202 were presented at AACR 2026, showing encouraging tumor targeting with tolerability that supported further dose escalation.Radiopharm initiated two first-in-human studies, dosing first patients in Lu177-RV-01 across various tumor types and Tb161-RAD402 in advanced prostate cancer.Company guided to additional RAD202 and RAD204 dose-cohort readouts in mid-2026, setting up near-term clinical catalysts for pipeline valuation.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL8vzXqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","IE00B3QW5Z07.USD","BK4112","SG9999014039.USD","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD","SG9999014005.SGD","NDAQ","BK7067","IE00BN0W2V16.EUR","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","LU0314104364.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629605001","title":"Radiopharm Theranostics Reports Decline in Cash at End of March","url":"https://stock-news.laohu8.com/highlight/detail?id=2629605001","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629605001?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:18","pubTimestamp":1776921523,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) said it closed the March quarter with a cash position of AU$19.2 million, down from AU$34.5 million at the end of the previous quarter, according to a Thursday filing","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":66,"code":"91000000","status":"200"}]}}